• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性转甲状腺素蛋白淀粉样变性:分子基础与治疗策略

Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.

作者信息

Saraiva Maria João Mascarenhas

机构信息

Amyloid Unit, Institute for Cellular and Molecular Biology, University of Porto, R. Campo Alegre, 823. 4150-180 Porto, Portugal.

出版信息

Expert Rev Mol Med. 2002 May 14;4(12):1-11. doi: 10.1017/S1462399402004647.

DOI:10.1017/S1462399402004647
PMID:14987380
Abstract

Transthyretin (TTR) is a transport protein for thyroid hormones and vitamin A and might have an important role in the nervous system. However, TTR can undergo a conformational change and form amyloid fibrils, in both acquired and hereditary forms of systemic amyloidosis. More than 80 TTR mutations have been associated with autosomal dominant amyloidosis, usually presenting with peripheral and autonomic neuropathy and/or cardiomyopathy. Major areas of research in TTR amyloidosis include: molecular mechanisms leading to fibril formation; mechanisms of fibril-induced cell death; modulators of phenotypic expression of the disease; and therapeutic strategies.

摘要

转甲状腺素蛋白(TTR)是一种甲状腺激素和维生素A的转运蛋白,可能在神经系统中发挥重要作用。然而,在获得性和遗传性全身性淀粉样变性中,TTR可发生构象变化并形成淀粉样纤维。超过80种TTR突变与常染色体显性淀粉样变性相关,通常表现为周围神经和自主神经病变及/或心肌病。TTR淀粉样变性的主要研究领域包括:导致纤维形成的分子机制;纤维诱导细胞死亡的机制;疾病表型表达的调节因子;以及治疗策略。

相似文献

1
Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.遗传性转甲状腺素蛋白淀粉样变性:分子基础与治疗策略
Expert Rev Mol Med. 2002 May 14;4(12):1-11. doi: 10.1017/S1462399402004647.
2
Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation.伴有或不伴有肝移植的遗传性转甲状腺素蛋白淀粉样变性中甲状腺淀粉样变的临床病理及生化表现
Amyloid. 2017 Mar;24(1):24-29. doi: 10.1080/13506129.2016.1276440. Epub 2017 Jan 13.
3
Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation.遗传性转甲状腺素蛋白淀粉样变性患者肝移植后心脏淀粉样蛋白沉积的进展
Amyloid. 2007 Dec;14(4):277-82. doi: 10.1080/13506120701614032.
4
Transthyretin-related hereditary amyloidosis in a Chinese family with TTR Y114C mutation.载脂蛋白相关遗传性淀粉样变性病一家系 TTR Y114C 突变
Neurodegener Dis. 2011;8(4):187-93. doi: 10.1159/000321679. Epub 2010 Dec 3.
5
Transthyretin amyloidosis: a tale of weak interactions.转甲状腺素蛋白淀粉样变性:弱相互作用的故事。
FEBS Lett. 2001 Jun 8;498(2-3):201-3. doi: 10.1016/s0014-5793(01)02480-2.
6
Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.从一名被诊断为家族性转甲状腺素蛋白淀粉样变性病的患者中鉴定出一种新型转甲状腺素蛋白Phe33Cys变体的S-磺化和S-硫醇化。
Protein Sci. 2003 Aug;12(8):1775-85. doi: 10.1110/ps.0349703.
7
Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease.携带人类致病 Ile122 等位基因的老年恒河猴发生转甲状腺素蛋白淀粉样变性:人类疾病的有效病理模型。
Lab Invest. 2012 Mar;92(3):474-84. doi: 10.1038/labinvest.2011.195. Epub 2011 Dec 19.
8
Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis.淀粉样纤维成分与遗传性转甲状腺素蛋白V30M淀粉样变性的表型相关。
J Pathol. 2008 Oct;216(2):253-61. doi: 10.1002/path.2411.
9
Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.老年系统性淀粉样变中的淀粉样纤维成分与转甲状腺素蛋白基因结构
Lab Invest. 1995 Nov;73(5):703-8.
10
Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.
J Struct Biol. 2000 Jun;130(2-3):290-9. doi: 10.1006/jsbi.2000.4273.

引用本文的文献

1
Fragment-based drug discovery for transthyretin kinetic stabilisers using a novel capillary zone electrophoresis method.使用新型毛细管区带电泳方法发现用于转甲状腺素蛋白动力学稳定剂的基于片段的药物
PLoS One. 2025 May 14;20(5):e0323816. doi: 10.1371/journal.pone.0323816. eCollection 2025.
2
Technologies for Targeted RNA Degradation and Induced RNA Decay.靶向RNA降解与诱导RNA衰变技术
Chem Rev. 2024 Dec 11;124(23):13301-13330. doi: 10.1021/acs.chemrev.4c00472. Epub 2024 Nov 5.
3
Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry.
用于 RNA 治疗的有效工具:siRNA 干扰或 miRNA 模拟。
Theranostics. 2021 Aug 11;11(18):8771-8796. doi: 10.7150/thno.62642. eCollection 2021.
4
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.治疗蛋白质错误折叠疾病:针对全身性淀粉样变性的治疗成功案例
Front Pharmacol. 2020 Jul 10;11:1024. doi: 10.3389/fphar.2020.01024. eCollection 2020.
5
Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations.遗传性血清甲状腺激素结合蛋白突变患者的临床识别和评估。
J Endocrinol Invest. 2020 Jan;43(1):31-41. doi: 10.1007/s40618-019-01084-9. Epub 2019 Jul 27.
6
Systemic amyloidoses and proteomics: The state of the art.系统性淀粉样变性与蛋白质组学:现状
EuPA Open Proteom. 2016 Feb 23;11:4-10. doi: 10.1016/j.euprot.2016.02.003. eCollection 2016 Jun.
7
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).转甲状腺素蛋白淀粉样变性患者的基因型和表型对心脏生物标志物的影响——转甲状腺素蛋白淀粉样变性结局调查(THAOS)报告
PLoS One. 2017 Apr 6;12(4):e0173086. doi: 10.1371/journal.pone.0173086. eCollection 2017.
8
Discordant results between biochemical and molecular transthyretin assays: lessons learned from a unique testing algorithm at the Mayo Clinic.转甲状腺素蛋白生化检测与分子检测结果不一致:梅奥诊所独特检测算法的经验教训
J Genet. 2013 Dec;92(3):599-604. doi: 10.1007/s12041-013-0303-6.
9
Pathophysiology and treatment of systemic amyloidosis.系统性淀粉样变性的病理生理学和治疗。
Nat Rev Nephrol. 2013 Oct;9(10):574-86. doi: 10.1038/nrneph.2013.171. Epub 2013 Aug 27.
10
Distinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrils.沿转甲状腺素蛋白淀粉样原纤维的组装和去组装途径捕获的独特环形寡聚物。
PLoS One. 2012;7(9):e44992. doi: 10.1371/journal.pone.0044992. Epub 2012 Sep 12.